Literature DB >> 25917887

Prostate cancer: PREVAILing wind blows more good news for enzalutamide.

Annette Fenner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25917887     DOI： 10.1038/nrurol.2015.94

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Authors:  Yohann Loriot; Kurt Miller; Cora N Sternberg; Karim Fizazi; Johann S De Bono; Simon Chowdhury; Celestia S Higano; Sarah Noonberg; Stefan Holmstrom; Harry Mansbach; Frank G Perabo; De Phung; Cristina Ivanescu; Konstantina Skaltsa; Tomasz M Beer; Bertrand Tombal
Journal:  Lancet Oncol       Date:  2015-04-14       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.